The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 9, 2005, Pages 865-874

  Kilkens, T O C ^a,b,e   Honig, A ^c   Fekkes, D ^d   Brummer, R J M ^b,e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; PROLACTIN; SEROTONIN;

ADULT; AFFECT; ARTICLE; BRAIN; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DIARRHEA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTESTINE; INTESTINE DISTENSION; IRRITABLE COLON; MALE; MEMORY; MENTAL PERFORMANCE; MOOD; NEUROENDOCRINOLOGY; PERCEPTION; PERFORMANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROVOCATION TEST; SCORING SYSTEM; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM; VISCERA;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; AFFECT; BRAIN; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRACT; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; IRRITABLE BOWEL SYNDROME; MALE; MEMORY; MIDDLE AGED; PAIN MEASUREMENT; PERCEPTION; PROLACTIN; RECTUM; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 27644456167     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02660.x     Document Type: Article

References (48)

1. Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 1-9.
2. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia [see comments]. Gastroenterology 1994; 107: 271-93.
3. Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 2004; 20: 1195-203.
4. Kilkens TO, Honig A, Rozendaal N, Van Nieuwenhoven MA, Brummer RJ. Serotonergic modulators in the treatment of irritable bowel syndrome - influence on psychiatric and gastrointestinal symptoms. Aliment Pharmacol Ther 2003; 17: 43-51.
5. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59 (Suppl. 14): 11-4.
6. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut 2002; 51 (Suppl. 1): 181-6.
7. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxy-tryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-70.
8. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial [see comments]. Lancet 2000; 355: 1035-40.
9. Kilkens TO, Honig A, van Nieuwenhoven MA, Riedel WJ, Brummer RJ. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004; 53: 1794-800.
10. Yatham LN, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci 1993; 53: 447-63.
11. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 277-95.
12. Kapitany T, Schindl M, Schindler SD, et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88: 75-88.
13. Gorard DA, Dewsnap PA, Medbak SH, et al. Central 5-hydroxytryptaminergic function in irritable bowel syndrome. Scand J Gastroenterol 1995; 30: 994-9.
14. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004; 141: 1285-93.
15. Sheehan D. MINI International Neuropsychiatric Interview. Tampa, USA: University of South Florida, 1994.
16. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96.
17. Arrindell WA, Ettema JHM. SCL-90. Een multidimensionale psychopathologie indicator (SCL-90. A Multidimensional Indicator of Psychopathology). Lisse, the Netherlands: Swets & Zeitlinger, 1986.
18. Mykletun A, Stordal E, Dahl AA. Hospital Anxiety and Depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 2001; 179: 540-4.
19. Luteijn F, van der Ploeg FAE. Handleiding Groninger Intelligentie test (GIT) (Manual Groninger Intelligence Test). Lisse, the Netherlands: Swets and Zeitlinger, 1983.
20. Ledochowski M, Sperner-Unterweger B, Fuchs D. Lactose malabsorption is associated with early signs of mental depression in females: a preliminary report. Dig Dis Sci 1998; 43: 2513-7.
21. Sobczak S, Riedel WJ, Booij I, et al. Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar disorder patients and matched healthy control volunteers. Psychol Med 2002; 32: 503-15.
22. Drossman DA, Heaton K, Irvine EJ, Muller-Lissner S. Functional bowel disorders and functional abdominal pain. In: Drossman, DA, Corazziari, E, Talley, N, Thompson, WG, Whitehead, WE, eds. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: a Multinational Consensus. McLean, VA, USA: Degnon Associates, 2000: 351-98.
23. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 471-4.
24. Riedel WJ, Klaassen T, Deutz NE, van Someren A, van Praag HM. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology (Berl) 1999; 141: 362-9.
25. Mcnair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States (POMS) Manual. San Diego, CA, USA: Educational and Industrial Testing Service, 1992.
26. Stronks DL, Tulen JH, Verheij R, et al. Serotonergic, catecholaminergic, and cardiovascular reactions to mental stress in female migraine patients. A controlled study. Headache 1998; 38: 270-80.
27. Fekkes D, Timmerman L, Pepplinkhuizen L. Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. Eur Neuropsychopharmacol 1997; 7: 235-9.
28. Riedel WJ, Klaassen T, Griez E, et al. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology 2002; 26: 358-67.
29. Tack J, Sarnelli G. Serotonergic modulation of visceral Sensation: upper gastrointestinal tract. Gut 2002; 51 (Suppl. 1): 177-80.
30. Broekaert D, Vos R, Gevers A, et al. A double-blind randomised placebo-controlled crossover trial of citalopram, a selective serotonin reuptake inhibitor, in irritable bowel syndrome. Gastroenterology 2001; 120: A641.
31. Tack JF, Vos R, Broeckaert D, Fischler B, Janssens B. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man. Gastroenterology 2000; 118: A175.
32. Siproudhis L, Dinasquet M, Sebille V, Reymann JM, Bellissant E. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception. Aliment Pharmacol Ther 2004; 20: 689-95.
33. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-28.
34. Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002; 14: 241-7.
35. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl) 2002; 163: 106-10.
36. Harmer CJ, Bhagwagar Z, Perrett DI, et al. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 2003; 28: 148-52.
37. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 2004; 161: 1256-63.
38. Kemp AH, Gray MA, Silberstein RB, Armstrong SM, Nathan PJ. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. Neuroimage 2004; 22: 1084-96.
39. Paffen MLJE, Kilkens TOC, Honig A, Brummer R-JM, Van Nieuwenhoven MA. Does a rectal barostat procedure induce stress in IBS patients and healthy controls? Eur J Gastroenterol Hepatol 2003; 15: A38.
40. Seifritz E, Baumann P, Muller MJ, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996; 14: 253-63.
41. Lotrich FE, Bies R, Muldoon MF, et al. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology (Berl) 2005; 178: 268-75.
42. Henning J, Netter P. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int J Neuropsychopharmacol 2002; 5: 67-71.
43. Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004; 29: 1699-703.
44. Heitkemper M, Jarrett M, Cain K, et al. Increased urine catecholamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol 1996; 91: 906-13.
45. Patacchioli FR, Angelucci L, Dellerba G, Monnazzi P, Leri O. Actual stress, psychopathology and salivary cortisol levels in the irritable bowel syndrome (IBS). J Endocrinol Invest 2001; 24: 173-7.
46. Steckler T, Holsboer F, Reul JM. Glucocorticoids and depression. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 597-614.
47. Eichhammer P, Langguth B, Wiegand R, et al. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology (Berl) 2003; 166: 294-7.
48. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004; 53: 1452-8.